{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-02T03:51:41.292167+00:00","company":{"ticker":"ALLO","cik":1737287,"company_name":"Allogene Therapeutics, Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"43fe04daa5","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","payload":{"action":"will continue serving","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":true,"role":"Chief Medical Officer (interim)","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Zachary Roberts changed role as Chief Medical Officer (interim) at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Roberts currently serves as the Company’s Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company’s Chief Medical Officer on an interim basis following the Effective Date.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-26-245484","anchor_url":"https://secwatch.observer/filing/0001193125-26-245484#claim-43fe04daa5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm"},{"fact_type":"executive_change","fact_key":"d2e8883ed6","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Zachary Roberts was appointed as Class I director at Allogene Therapeutics, Inc..","evidence_excerpt":"Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-245484","anchor_url":"https://secwatch.observer/filing/0001193125-26-245484#claim-d2e8883ed6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm"},{"fact_type":"executive_change","fact_key":"1bad2c1b70","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":false,"role":"non-employee director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Chang was appointed as non-employee director at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Chang will remain on the Board and will become a non-employee director commencing on the Effective Date","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-245484","anchor_url":"https://secwatch.observer/filing/0001193125-26-245484#claim-1bad2c1b70","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm"},{"fact_type":"executive_change","fact_key":"251b68b71b","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-06-30","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Zachary Roberts","successor_named":true},"claim":"David Chang resigned as President and Chief Executive Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"Dr. Chang’s last day of service in these positions will be June 30, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-245484","anchor_url":"https://secwatch.observer/filing/0001193125-26-245484#claim-251b68b71b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm"},{"fact_type":"executive_change","fact_key":"18865b97bf","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2026-05-28T21:06:28+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-07-01","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":true},"claim":"Zachary Roberts was appointed as President and Chief Executive Officer at Allogene Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company’s President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-245484","anchor_url":"https://secwatch.observer/filing/0001193125-26-245484#claim-18865b97bf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312526245484/0001193125-26-245484-index.htm"},{"fact_type":"executive_change","fact_key":"bb68147969","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2025-01-29T23:59:59+00:00","payload":{"action":"leaving employment","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-28","interim":false,"role":null,"role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Timothy Moore departed as other_named_officer at Allogene Therapeutics, Inc..","evidence_excerpt":"On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-014985","anchor_url":"https://secwatch.observer/filing/0001193125-25-014985#claim-bb68147969","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000119312525014985/0001193125-25-014985-index.htm"},{"fact_type":"executive_change","fact_key":"39b3eee75f","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"replaced","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-06-05","interim":false,"role":"principal accounting officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Geoffrey Parker changed role as principal accounting officer at Allogene Therapeutics, Inc..","evidence_excerpt":"Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001737287-24-000050","anchor_url":"https://secwatch.observer/filing/0001737287-24-000050#claim-39b3eee75f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm"},{"fact_type":"executive_change","fact_key":"fdf4c8d742","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-06-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-05","interim":false,"role":"principal accounting officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Annie Yoshiyama was appointed as principal accounting officer at Allogene Therapeutics, Inc..","evidence_excerpt":"appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001737287-24-000050","anchor_url":"https://secwatch.observer/filing/0001737287-24-000050#claim-fdf4c8d742","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm"},{"fact_type":"earnings_release","fact_key":"a9c25908bb65e09dc37274c1275539619f237b8f","cik":1737287,"ticker":"ALLO","company_name":"Allogene Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Allogene Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001737287-24-000040","anchor_url":"https://secwatch.observer/filing/0001737287-24-000040#claim-a9c25908bb65e09dc37274c1275539619f237b8f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000040/0001737287-24-000040-index.htm"}]}